Clinical Trial Detail

NCT ID NCT03055013
Title Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

renal cell carcinoma

Therapies

Nivolumab

Age Groups: senior adult

No variant requirements are available.